Placebo-controlled study on the pharmacokinetics, pharmacodynamics, safety and tolerability of concurrent valproate [valproic acid] and bifeprunox administration in subjects with bipolar I disorder
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Bifeprunox (Primary) ; Valproic acid
- Indications Bipolar I disorders
- Focus Pharmacokinetics
- Sponsors Solvay Pharmaceuticals
- 07 Sep 2007 Status changed from in progress to completed.
- 31 Dec 2005 New trial record.